W. L. Gore & Associates Inc. has received U.S. Food and Drug Administraion (FDA) approval for the new large diameter 35 mm trunk-ipsilateral leg and 36 mm aortic extender components, as well as the lower profile 31 mm diameter trunk-ipsilateral leg and 32 mm aortic extender components of the Gore Excluder AAA Endoprosthesis. The new components provide physicians with a proven and durable endovascular option to treat abdominal aortic aneurysms (AAAs).

Tyrx Inc. has received a license from Health Canada to market its new AigisRx R Fully Resorbable Antibacterial Envelope technology with implantable electronic devices (IEDs). The AigisRx R Antibacterial Envelope is specifically designed to stabilize IEDs while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation. Tyrx is the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections.

The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD live longer and are less likely to suffer a non-fatal heart attack when treated with bypass surgery instead of drug-eluting stents (DES), tiny, medicine-coated mesh tubes that prop open clogged arteries.

Samsung Electronics America Inc. announced the Samsung Ugeo H60, the first ultrasound system integrating Samsung technology and design introduced to the U.S. medical imaging market. The Samsung Ugeo H60 ensures superior imaging performance and a sleek design that provides users with a fast, accurate and intuitive ultrasound experience.

Angiotech Pharmaceuticals Inc. announced that it entered into a definitive agreement to sell certain of its subsidiaries, comprising Angiotech's interventional products business, to Argon Medical Devices Inc., a portfolio company of RoundTable Healthcare Partners, for $362.5 million in cash consideration. Angiotech expects the transaction will close prior to the end of April 2013.

Archimedes IndiGo — the physician and patient decision-support tool created by Archimedes, Inc. — was chosen last summer as the risk-assessment engine for the new $100,000 mobile app challenge sponsored by the Office of the National Coordinator (ONC). As part of the U.S. Department of Health and Human Services' Million Hearts "Risk Check Challenge," the ONC invited developers to create a mobile app that would help consumers take a heart-health risk assessment, direct them to health-screening locations in their community and use the results to work with their doctor to develop a plan for improving their heart health.

Transesophageal Echocardiogram

The American Society of Echocardiography (ASE) has released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of the ABIM Foundation, along with Consumer Reports. Fifth on the list, they ask that patients and their doctors talk about the real need for a TEE if the patient’s clot treatment isn’t likely to be modified.

Terumo Cardiovascular Systems announced it has entered into a multi-year distribution agreement with Nonin Medical, Inc. Beginning May 1, 2013, Terumo CVS will distribute Nonin's Equanox Model 7600 Regional Oximetry System to adult and pediatric cardiovascular hospitals in the U.S. Nonin's direct sales force will focus on certain non-cardiovascular applications in those hospitals and applications in all other U.S. hospitals. Terumo CVS manufactures and markets medical devices for the global cardiac surgery market. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now